



Final Appraisal Recommendation

Advice No: 2715 – October 2015

**Insulin degludec/liraglutide (Xultophy®)
100 units/3.6 mg per ml solution for injection**

Submission by Novo Nordisk Ltd

Recommendation of AWMSG

Insulin degludec/liraglutide (Xultophy®) is recommended as an option for restricted use within NHS Wales.

Insulin degludec/liraglutide (Xultophy®) is licensed for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to other oral medicinal products for the treatment of diabetes.

Insulin degludec/liraglutide (Xultophy®) is restricted for use in combination with oral glucose-lowering medicinal products when these combined with basal insulin do not provide adequate glycaemic control.

Insulin degludec/liraglutide (Xultophy®) is not recommended for use within NHS Wales outside of this subpopulation.

Additional note(s):

- Insulin degludec/liraglutide (Xultophy®) should be prescribed by brand name to avoid medication errors.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2544), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Novo Nordisk
Date of first issue	October 2015
Last reviewed	September 2020

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2715:
insulin degludec/liraglutide (Xultophy®). October 2015.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendations. Accreditation is valid for 5 years from October 2016. More information on accreditation can be viewed at <http://www.nice.org.uk/about/what-we-do/accreditation>